Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Hyperlipidemia

Subtypes of Hyperlipidemia

Hypertriglyceridemia 7 Hypercholesterolemia 6 Familial hypercholesterolemia 2 Familial combined hyperlipidemia 1

31 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hyperlipidemia

89 trials tracked for Hyperlipidemia: 35 in phase 3 or 4 and 13 with published results. The most-cited published study has 511 citations.

89Trials tracked

35Phase 3 & 4

0Recruiting

13With published results

Phase distribution

Phase 4 11 Phase 3 24 Phase 2 15 Phase 1 5 Other / NA 34

Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 Completed · 511 cited
Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events Completed · 363 cited
Phase 3 Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia Completed · 363 cited
Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events Completed · 363 cited
Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins Completed · 363 cited
Phase 3 A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy Completed · 360 cited

Show 44 more trials

Phase 4 Stop Atherosclerosis in Native Diabetics Study Completed · 247 cited
Phase 4 Self-Assessment Method for Statin Side-effects Or Nocebo Completed · 180 cited
Phase 4 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Completed · 97 cited
Phase 3 Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events Completed · 60 cited
Phase 3 Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults Completed · 38 cited
Phase 3 Effect of Evolocumab on Coronary Atherosclerosis Completed · 14 cited
Phase 4 Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation Completed · 2 cited
Phase 4 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood Completed
Phase 4 Lipid Management in Renal Transplant Recipients Using Evolocumab. Completed
Phase 4 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients Completed
Phase 4 Telephone Based Management of Hyperlipidemia Completed
Phase 4 A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction Completed
Phase 4 Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin Completed
Phase 4 Effects of Omega-3 Fatty Acids on the Human Gene Expression Completed
Phase 3 Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans Completed
Phase 3 A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia Completed
Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 Completed
Phase 3 Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 Completed
Phase 3 An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Completed
Phase 3 Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin Completed
Phase 3 Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study Completed
Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed
Phase 3 Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 Completed
Phase 3 Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy Completed
Phase 3 Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Completed
Phase 3 Effect of MK0524A on Cholesterol Levels (0524A-048) Completed
Phase 3 Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress Completed
Phase 3 Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia Completed
Phase 3 An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) Completed
Phase 2 Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Completed
Phase 2 Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease Completed
Phase 2 Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Completed
Phase 2 Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS Completed
Phase 2 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Completed
Phase 2 Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed
Phase 2 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease Completed
Phase 2 Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease Completed
Phase 2 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed
Phase 2 The SCCS Polypill Pilot Trial Completed
Phase 2 Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia. Completed
Phase 2 Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia Completed
Phase 2 A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Completed
Phase 2 LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy Completed
Phase 2 The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

‹ Prev 1 2 3

Questions about Hyperlipidemia

What are the research gaps regarding using Rhaponticum for Hyperlipidemia?

Research on Rhaponticum for hyperlipidemia is limited to preclinical studies; no human trials confirm its lipid-lowering effects, safety, or dosing.

Full answer →

How does Crestor lower cardiovascular risk for adults with elevated cholesterol levels?

Crestor (rosuvastatin) lowers cardiovascular risk by reducing LDL cholesterol and inflammation, as shown in clinical trials and real-world studies.

Full answer →

Is there evidence that quercetin is effective for managing Hyperlipidemia?

Quercetin shows promise for hyperlipidemia in lab and animal studies, but human clinical evidence is still lacking. It is not a proven treatment.

Full answer →

Will Rhaponticum species help treat my condition known as Hyperlipidemia?

Rhaponticum species show hypolipidemic effects in animal and lab studies, but human clinical trials are lacking, so it is not a proven treatment for hyperlipidemia.

Full answer →